FINWIRES · TerminalLIVE
FINWIRES

Climb Bio's CLYM116 Data Could Show Competitive Position in IgA Nephropathy Market, Oppenheimer Says

By

Climb Bio's (CLYM) CLYM116 could stand out in the growing IgA nephropathy treatment market if Thursday's phase 1 data shows strong and lasting APRIL and IgA reductions that support less frequent dosing, Oppenheimer said in a note Wednesday.

The key question for Thursday's results is whether CLYM116 can deliver strong and durable effects that could support an infrequently administered under-the-skin treatment, Oppenheimer said.

The investment firm said other approved and experimental anti-APRIL drugs have already shown that targeting APRIL can work in IgAN, setting a benchmark for CLYM116.

The phase 2 portion of partner Mabworks' phase 1/2 IgAN study is expected to begin before the end of the quarter, with Climb Bio planning to present additional CLYM116 data at a medical meeting in Q4, the firm noted.

Oppenheimer kept its outperform rating and $18 price target for Climb Bio.

Price: $14.62, Change: $-0.21, Percent Change: -1.38%

Related Articles

Wire

American Healthcare REIT Closes $572 Million in Initial Kensington Senior Living Acquisitions

American Healthcare REIT (AHR) completed the acquisitions of six Kensington Senior Living communities comprising 464 units for $572 million.Two additional communities are subject to definitive purchase agreements and are expected to close in Q4, subject to conditions, American Healthcare said Tuesday in a statement.The full eight-community portfolio has 745 units with an aggregate contract purchase price of $873 million, the company said. Kensington will continue operating the communities after the closings.The transaction establishes a long-term strategic partnership, American Healthcare said.American Healthcare shares rose 3.6% in after-hours trading.

$AHR
Wire

Gitlab Q2 Adjusted EPS Flat, Revenue Rises; Q3 Guidance Set

Gitlab (GTLB) reported Tuesday Q2 adjusted earnings of $0.24 per diluted share, unchanged from a year earlier.Analysts polled by FactSet expected $0.18.Revenue for the quarter ended July 31 was $286.3 million, up from $236.0 million a year ago.Analysts expected $273.1 million.GitLab expects Q3 adjusted EPS of $0.19 to $0.20 on revenue of $281 million to $283 million. Analysts expect $0.18 and $280.9 million, respectively.For fiscal 2027, the company currently expects adjusted EPS of $0.85 to $0.87 on revenue between $1.129 billion and $1.133 billion. Analysts expect $0.81 and $1.12 billion, respectively.

$GTLB
Wire

Honeywell Aerospace to Pay Over $2 Million in US Defense Contract Settlement, Shares Fall

Honeywell Aerospace (HONA) has agreed to pay over $2 million to settle allegations that it failed to comply with cybersecurity requirements in a US Department of Defense contract, the US Department of Justice said Tuesday.The settlement resolves allegations that, from April 2020 through Dec. 2023, a unit of Honeywell International (HON) submitted false claims for payment after failing to meet cybersecurity requirements for one of Honeywell's networks.Honeywell Aerospace became a standalone company on June 29 after separating from Honeywell International.Shares of Honeywell Aerospace were down 2.4% in late afternoon trading.Price: $154.42, Change: $-3.69, Percent Change: -2.33%

$HON$HONA